Abstract: A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol and/or lean body mass in humans and animals. The method comprises administering policosanol and chromium and/or chromium salts which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and/or chromium salts.

Abstract: A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

Abstract: The present invention provides compositions and methods for treating or preventing the development of inflammatory disorder of the gastrointestinal tract in a subject, comprising administering to a subject therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol). Inflammatory conditions that can be addressed by the compositions and methods of this invention include colorectal cancer, neoplasm of the colon, neoplasm of the rectum, ulcerative colitis, adenomatous polyps, familial polyposis, stomach cancer, and combinations thereof.

Abstract: A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and/or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.

Abstract: The present invention provides methods for treating or preventing the development of macular degeneration-related disorders in a subject, including humans by administering to a subject therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol).

Abstract: A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.

Abstract: The present invention provides methods for the treatment and/or amelioration of inflammation in a subject, including humans, by administering to a subject a therapeutically effective amount of a biologically active mixture of high purity, high molecular weight straight chain primary aliphatic alcohols (referred to collectively herein as policosanol). Also included are methods of reducing levels of C-reactive protein in a subject, comprising administering to a subject a therapeutically effective amount of policosanol.

Abstract: A composition is provided which contains policosanol and niacin and/or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and niacin and/or niacin derivatives which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to niacin and/or niacin derivatives.

Abstract: A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and/or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

Abstract: The present invention relates to improved dosage forms of pharmaceuticals for treating rhinitis associated with allergies and colds. The dosage forms include an effective amount each of a non-steroidal anti-inflammatory drug, and a decongestant or an antihistamine wherein the effective amount of the decongestant or antihistamine is less than 75% of an amount present in an approved dose of the decongestant or the antihistamine relative to an amount of the NSAID corresponding to about 100% of the amount present in a normal strength dosage form of the NSAID.

Abstract: The present invention is directed to a pharmaceutical composition and method for treatment of rhinitis and cold like symptoms, the composition includes a non-steroidal anti-inflammatory drug (NSAID), a decongestant and an antihistamine preferably in a multi-layer tablet comprising an immediate release layer and an extended release layer to optimize the delivery profile and match the duration of biological action of the multiple active agents.

Abstract: The present invention provides a coating system for solid pharmaceutical dosage units, such as tablets. The coating system comprising (a) a subcoat; (b) an optional colorcoat; and (c) a polish coat. In a preferred embodiment, the present invention provides (a) a subcoat comprising (i) hydroxypropyl methylcellulose (HPMC) and (ii) a polysaccharide; (b) a colorcoat comprising (i) a colorant and (ii) a polysaccharide which may be the same as or different from the polysaccharide of the subcoat; and (c) a polish coat comprising (i) a polyethylene glycol and, optionally, (ii) a wax. Also disclosed is a method for providing gloss to a coated pharmaceutical solid dosage unit by coating a pharmaceutical core with the aforementioned polish coat.

Abstract: The present invention provides a coating system for solid pharmaceutical dosage units, such as tablets. The coating system comprising (a) a subcoat; (b) an optional colorcoat; and (c) a polish coat. In a preferred embodiment, the present invention provides (a) a subcoat comprising (i) hydroxypropyl methylcellulose (HPMC) and (ii) a polysaccharide; (b) a colorcoat comprising (i) a colorant and (ii) a polysaccharide which may be the same as or different from the polysaccharide of the subcoat; and (c) a polish coat comprising (i) a polyethylene glycol and, optionally, (ii) a wax. Also disclosed is a method for providing gloss to a coated pharmaceutical solid dosage unit by coating a pharmaceutical core with the aforementioned polish coat.

Abstract: A method for preventing heartburn episodes in a patient susceptible to suffering heartburn episodes following ingestion of heartburn-inducing food or beverage, comprising administering to the patient, 30 minutes prior to consumption by the patient of the food or beverage, a composition comprising an amount of famotidine of 10 mg.

Abstract: A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.